Introduction
Combination therapy with upfront all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy for induction and consolidation, as well as ATRA-based maintenance, has dramatically improved the outcomes of patients with acute promyelocytic leukemia (APL). 1, 2 This treatment strategy is currently the standard of care for newly diagnosed APL patients. However, relapse occurs in about 20% of patients receiving ATRA and chemotherapy, and is still a major obstacle to cure for APL patients. [3] [4] [5] [6] A recent multivariate analysis revealed that APL patients with a WBC count of more than 10 Â 10 9 /L at initial presentation have a significantly increased relapse risk and poorer survival. 1, 3, 7 New strategies include risk-adapted therapies to intensify the use of anthracyclines and/or cytarabine (CA) in either induction or consolidation of high-risk APL patients. 1, 8, 9 Autologous hematopoietic SCT (HSCT) has been widely used to consolidate remission in patients with acute myelogenous leukemia. 10, 11 As new risk-adapted treatment strategies combined with upfront ATRA have provided higher cure rates, HSCT might not always be necessary for APL patients who are in the first complete molecular remission at the end of consolidation. 12 Therefore, the role of HSCT in the front-line APL therapy has changed during recent years. In this paper, we use historical data to report the long-term safety and therapeutic efficacy of myeloablative therapy followed by autologous PBSCT (auto-PBSCT) in 20 APL patients in the first CR (CR1) and six patients in the second CR (CR2). We discuss the role of auto-HSCT for APL patients based on our observations and previously reported literature.
Materials and methods

Patient characteristics
Between April 1992 and November 2008, 26 APL patients, who were treated with myeloablative conditioning followed by auto-PBSCT in remission, were enrolled in this study at seven institutions of the Fukuoka Blood & Marrow Transplant Group (FBMTG). All patients were diagnosed as APL morphologically according to the FAB classification. The diagnosis was also confirmed by the presence of t(15; 17)(q22; q21) by karyotypic analysis and/or detection of the PML/RARa transcript by reverse transcription PCR (RT-PCR).
Clinical characteristics of these patients are listed in Table 1 . The patients comprised 14 males and 12 females with a median age of 45 years (16-68 years) . Of these 26 patients, 20 received upfront auto-PBSCT in CR1 between April 1992 and November 2002. Five of these 20 patients had a WBC count of more than 10 Â 10 9 /L and were considered as high-risk patinets, 1, 3, 7 and six patients showed additional karyotypic abnormalities with t(15;17) at presentation (Table 1) . In contrast, after August 1993, according to the policy of each institution, APL patients in molecular CR1 after consolidation are no longer always indicated for upfront auto-PBSCT. Consequently, six patients received auto-PBSCT in CR2 during the period up to November 2008, although all of these six patients had a WBC count of less than 10 Â 10 9 /L at presentation, but had a relapse of APL after cessation of maintenance therapy for CR1. This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. In 20 patients who were assigned to receive upfront auto-PBSCT in CR1, auto-PBSCs were collected during the hematopoietic recovery phase after the second course of consolidation followed by G-CSF (filgrastim; Kyowa Hakko Kirin, Japan). Collected and unmanipulated PBSCs were cryopreserved until transplantation. The remaining six patients after the second consolidation chemotherapy were treated with an additional course of intermediate-dose CA combined with DNR 25 mg/m 2 for 4 days, followed by treatment with ATRA, and low-dose MTX and mercaptopurine as maintenance therapy as described by Sanz et al. Thereafter, these six patients, who had a WBC count of less than 10 Â 10 9 /L at presentation and were considered as low-risk patients, had a relapse of leukemia at a median of 22 months (8-54 months) after diagnosis. Three patients showed molecular relapse, which was detected by RT-PCR, whereas the remaining three patients showed hematologic relapse. Three patients received re-induction cytotoxic chemotherapy without arsenic trioxide (ATO), and the remaining three patients received ATO 0.15 mg/m 2 with or without idarubicin. All six patients achieved molecular CR2 after one course of re-induction chemotherapy. AutoPBSCs were collected after an additional two or three course of consolidation chemotherapy in these patients.
Chemotherapy and collection of PBSCs
Auto-PBSCT
The pretransplant conditioning regimen for all patients consisted of BU 1 mg/kg every 6 h orally on days À8 to À5, etoposide 20 mg/kg i.v. on days À4 and À3 and CA 3 g/m 2 i.v. every 12 h on days À3 and À2 (BEA regimen). 10, 13 Concurrently, G-CSF was administered to prime residual leukemic cells at a dose of 5 mg/kg on days À14 to À6, 10 mg/kg on days À5 to À4 in combination with continuous infusion of CA 100 mg/m 2 i.v. on days À12 to À6. Cryopreserved PBSCs were rapidly thawed in a 37 1C water bath and infused on day 0.
RT-PCR analysis
Nested RT-PCR analysis of PML/RARa chimeric mRNA was performed to detect minimal residual disease (MRD) with sensitivity threshold between 10 À6 and 10 À7 in PBSC samples in 15 of 20 patients who underwent auto-PBSCT in CR1, and BM samples in all six patients just before auto-PBSCT in CR2 as described previously. 14 
Results
Auto-PBSCT in CR1
Twenty patients received upfront high-dose chemotherapy (G-SCF-combined BEA regimen) with auto-PBSCT during CR1 after a median of 6 months (5-13 months) from the initial diagnosis. A median dose of 7.1 Â 10 6 CD34 þ cells/ kg was transplanted. No engraftment failure was observed. The median days to reach a granulocyte count above 0.5 Â 10 9 /L, a plt count above 20 Â 10 9 /L, and independence from plt transfusion was 15 days (range, 13-24 days), 11 days (range, 8-210 days) and 11 days (range, 6-191 days), respectively. No treatment-related deaths were observed after auto-PBSCT. Grades 1-2 stomatitis and diarrhea occurred in most recipients; however, significant adverse events, which were graded in accordance with National Cancer Institute Common Toxicity Criteria (version 2.0), above grade 3 were not observed.
At a median follow-up time of 133 months (73-193 months), all of 20 patients were continuing CR1 without maintenance therapy. Nested RT-PCR analysis was performed to test contamination of the infused PBSCs with APL cells. PML/RARa chimeric mRNA was undetectable in PBSCs samples obtained from all 15 patients. After auto-PBSCT (median follow-up time, 43 months), MRD could not be detected in BM samples from any of these patients (Table 1) .
Auto-PBSCT in CR2
Six patients, who had relapse but achieved CR2 after re-induction chemotherapy, were assigned to receive auto-PBSCT. RT-PCR analyses of BM samples obtained from all six patients before auto-PBSCT were negative for MRD (Table 1) . They received G-SCF-combined BEA regimen followed by auto-PBSCT after a median of 26 months (12-61 months) from the initial diagnosis. A median dose of 6.1 Â 10 6 CD34 þ cells/kg was transplanted. Engraftment was documented in all six patients. The median days to reach a granulocyte count above 0.5 Â 10 9 /L, a plt count above 20 Â 10 9 /L and independence from plt transfusion was 11 days (range, 9-12 days), 14 days (range, 11-15 days) and 11 days (range, 8-15 days), respectively. No treatment-related deaths and no significant adverse events above grade 3 were documented. No significant difference was observed in hematopoietic recovery or adverse effect between 20 and 6 patients in CR1 and CR2, respectively, after auto-PBSCT. All six patients who received transplantation in CR2 remained in CR at a median follow-up time of 41 months (2-187 months) without maintenance therapy.
Discussion
The European Cooperative Group for Blood and Marrow Transplantation (EBMT) group conducted a survey on APL patients who underwent HSCT between 1993 and 2003 in Europe. 15 In their analysis of 625 APL patients, the number of auto-HSCT has decreased progressively for patients in CR1 since 1998, whereas that for patients in CR2 has remained stable. The emergence of a new riskadapted treatment strategy combining ATRA and ATO has dramatically changed the role of auto-HSCT in the treatment of APL in CR1 and CR2. In contrast, allogeneic HSCT should be considered for patients with persistent MRD or without hematologic remission if an HLAmatched donor is available. 12 
Auto-HSCT in CR1
Large multicenter studies have shown that treatment regimens combining upfront ATRA and chemotherapy have provided high cure rates. [2] [3] [4] [5] [6] [7] In addition, multivariate analyses have revealed that the most important factor predicting relapse is a WBC count of more than 10 Â 10 9 /L at initial presentation. 1, 3, 7 Therefore, many investigators have tried to classify the risk for each patient and modulate the regimen to intensify the use of anthracyclines and/or CA in either induction or consolidation therapy for highrisk patients. 1, 9 A joint analysis by the Spanish cooperative group 'Programa para el Estudio de la Terape´utica en Hemopatı´a Maligna' (PETHEMA) and the European 'French-Belgian-Swiss APL' group compared the outcomes of PETHEMA LPA99 and European APL 2000 trials, and demonstrated that addition of high-dose of CA in consolidation has benefited high-risk patients. 5 Thereafter, through the combined analysis of APL93 and APL2000 trials, the European APL group confirmed a dramatically improved outcome of APL patients with high WBC counts when treated with escalating dose of CA in APL2000 trial: between these two trials, CR rate increased from 89 to 93%, and the 5-year cumulative incidence of relapse decreased from 40 to 9.5% in patients with high WBC counts (between 10 to 50 Â 10 9 /L). In patients with very high WBC counts of more than 50 Â 10 9 /L, the CR rate increased from 82 to 91%, and 5-year cumulative incidence of relapse decreased from 59 to 24%. 9 These results showed that upfront ATRA combined with intensified consolidation with high-dose CA has potential benefits for high-risk APL patients. Therefore, in terms of the intensification of chemotherapy, theoretically auto-PBSCT would be the best therapy to maximize the antileukemia effect and to minimize TRM by rapid engraftment, especially for highrisk patients, if TRM can be reduced as much as possible. In our study, upfront auto-PBSCT was performed in 20 APL patients in CR1 after consolidation, which included 5 high-risk patients. Engraftment was rapid, and TRM was not documented. All of these patients continued in CR for more than 10 years without maintenance therapy, indicating that leukemia-free survival (LFS) at 10 years was 100%. All infused PBSCs were negative for MRD in good-risk and high-risk patients who were examined (Table 1) . Thus, high-dose chemotherapy followed by auto-PBSCT and deep CR status, reflecting negative MRD in PBSCs, would have benefited our patients, as several reports indicated that molecular CR would be an important factor for patients autotransplanted in CR2. In contrast, according to the multicenter retrospective survey from the EBMT group, LFS at 5 years was B70% in 149 APL patients in CR1 receiving auto-HSCT, indicating that the results in APL patients autotransplanted in CR1 were not better than those in patients given ATRA-combining risk-adapted chemotherapy. 5 In addition, a long-term follow-up study with a median of 10 years of follow-up (APL 93 trial) recently revealed the benefits of prolonged maintenance with ATRA plus chemotherapy for high-risk patients with initial WBC counts of more than 5 Â 10 9 /L. 16 In these highrisk patients, cumulative incidence of relapse declined from 68.4% with no maintenance to 20.6% with combined ATRA and chemotherapy maintenance. On the basis of Auto-HSCT in CR2 For APL patients who had relapse after ATRA-containing regimens, ATO is presently considered as the best treatment option; 2-year OS was reported to be approximately between 50 and 60% after repeated cycles of ATO combined with chemotherapy in relapsed APL patients achieving CR2. 22, 23 The consolidation strategy after ATOinduced CR2 generally consists of HSCT, and the choice of transplant modality is mainly based on PCR status. Allogeneic HSCT is restrictively chosen for patients failing to achieve molecular CR2, as allogeneic HSCT offers greater antileukemic activity because of its GVL effect, but obviously involves a greater risk of TRM. 23 Auto-HSCT was recently considered to be one of the most useful options for consolidation in relapsed APL patients. 12, 15, 17, 23 In a report of the EBMT group, 195 APL patients in CR2 autotransplanted between 1993 and 2003 were enrolled in the survey; the 5-year estimate of LFS was 51%. 15 Although no data were available on re-induction and consolidation chemotherapy, or on PCR status of the graft and/or recipients before transplant, the results demonstrated that a large population of patients in CR2 achieved long-term OS after auto-HSCT. De Botton et al. 24 also discussed the benefit of auto-HSCT in 50 APL patients who relapsed after ATRA-containing treatment in 2004. The relapse-free survival at 7 years was 79.4% with a TRM of 6% after auto-HSCT. They analyzed MRD status in 30 available cases. PCR before auto-HSCT was positive in PBSCs in two cases and negative in 28 cases. One out of two cases autografted with a positive PCR assessment relapsed, and only three out of 28 cases (11%) autografted with negative PCR also relapsed. 24 In the patients autografted with negative PCR, relapse-free survival at 7 years increased to 87.3%, indicating that auto-HSCT would be Table 2 Comparison of outocomes from the studies in the autotransplanation for APL effective for the treatment of relapsed APL if performed in molecular CR2; this was consistent with previous reports [25] [26] [27] (Table 2) . Thomas et al. 28 reported their experience using ATO as re-induction therapy for 28 relapsed APL patients. Nine of 24 patients achieving molecular CR underwent auto-HSCT, and all of them continued in CR2 (2-year LFS and OS rates of 100%). In our study, six patients had a relapse of APL after cessation of maintenance therapy, although all six patients were considered as low-risk patients; three patients were treated with chemotherapy as re-induction for relapsed APL before the era of ATO, whereas the remaining three underwent ATO-containing chemotherapy. All six patients gained molecular CR2 after one course of re-induction chemotherapy, and PBSCs were collected after the subsequent chemotherapy (Table 1) . Six patients received auto-HSCT in CR2, and were continued in CR without maintenance at a median of 41 months (2-187 months). Furthermore, Thirugnanam et al. 29 recently showed that, following remission induction with an ATO-based regimen in relapsed APL patients, consolidation with auto-HSCT was associated with a significantly superior clinical outcome compared with ATO-based maintenance; EFS at 5 years was 83.3% in patients who underwent auto-HSCT vs 34.4% in those who did not. In addition, as recent evidence has revealed that ATO treatments comprising at least two cycles can result in molecular CR in nearly 80% of relapsed APL patients, 23 auto-HSCT may become more beneficial for APL patients in molecular CR2 receiving ATO treatment.
Intensification of pretransplant conditioning by G-CSF priming may have improved LFS in our study, especially patients with high risk and in CR2. G-CSF can stimulate the proliferation of myeloid leukemic cells because most express receptors for G-CSF, and increase susceptibility of leukemic cells to cell cycle-specific agent CA. Moreover, recent evidences have shown that G-CSF can mobilize hematopoietic stem/progenitor cells from BM niche by disruption of adhesion molecules such as CXCR4/SDF1 and VCAM1/VLA4. 30 In this context, G-CSF can also mobilize leukemic stem cells into circulation from BM niche, resulting in the increased susceptibility to chemotherapeutic agents. Clinical studies support a potential role to reduce leukemic relapse after HSCT or chemotherapy. 10, [31] [32] [33] [34] Large study will be required to assess further the efficacy of G-CSF priming for pretransplant conditioning.
Future perspective
Recently, Lee et al. 35 reported the importance of serial measurement of MRD by PCR analysis during therapy in 70 newly diagnosed APL patients. According to their prospective study, MRD after upfront ATRA and anthracycline-based induction chemotherapy was detectable in half of the patients and was undetectable in the remaining half. All patients negative for PCR after induction had a favorable clinical course thereafter, without relapse. In contrast, after the first consolidation, MRD was still detectable exclusively in about 30% of the patients positive for PCR after induction, who were highly susceptible to subsequent hematologic relapses, despite additional consolidation. 35 Therefore, patients who remain PCR positive after the first consolidation may be candidates requiring further ATO-containing treatment followed by HSCT: auto-HSCT has a strong anti-APL activity and potent roles in the treatment of APL, particularly in molecular CR, whereas allogeneic HSCT would be recommended for patients who fail to gain molecular CR. Large prospective studies and careful follow-ups with serial quantification of MRD would be needed to assess the value of an individualized, response-oriented treatment strategy and the role of HSCT in the treatment of APL patients.
